r-120758 and Disease-Models--Animal

r-120758 has been researched along with Disease-Models--Animal* in 1 studies

Other Studies

1 other study(ies) available for r-120758 and Disease-Models--Animal

Article	Year
In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent. Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:2 The activity of CS-758 (R-120758), a new triazole antifungal agent, was evaluated and compared with those of fluconazole, itraconazole, and amphotericin B in vitro and with those of fluconazole and itraconazole in vivo. CS-758 exhibited potent in vitro activity against clinically important fungi. The activity of CS-758 against Candida spp. was superior to that of fluconazole and comparable or superior to those of itraconazole and amphotericin B. CS-758 retained potent activity against Candida albicans strains with low levels of susceptibility to fluconazole (fluconazole MIC, 4 to 32 microg/ml). Against Aspergillus spp. and Cryptococcus neoformans, the activity of CS-758 was at least fourfold superior to those of the other drugs tested. CS-758 also exhibited potent in vivo activity against murine systemic infections caused by C. albicans, C. neoformans, Aspergillus fumigatus, and Aspergillus flavus. The 50% effective doses against these infections were 0.41 to 5.0 mg/kg of body weight. These results suggest that CS-758 may be useful in the treatment of candidiasis, cryptococcosis, and aspergillosis. Topics: Animals; Antifungal Agents; Aspergillus; Candida; Cryptococcus neoformans; Disease Models, Animal; Mice; Microbial Sensitivity Tests; Mycoses; Treatment Outcome; Triazoles	2002

Article

Year

In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent.

Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:2

The activity of CS-758 (R-120758), a new triazole antifungal agent, was evaluated and compared with those of fluconazole, itraconazole, and amphotericin B in vitro and with those of fluconazole and itraconazole in vivo. CS-758 exhibited potent in vitro activity against clinically important fungi. The activity of CS-758 against Candida spp. was superior to that of fluconazole and comparable or superior to those of itraconazole and amphotericin B. CS-758 retained potent activity against Candida albicans strains with low levels of susceptibility to fluconazole (fluconazole MIC, 4 to 32 microg/ml). Against Aspergillus spp. and Cryptococcus neoformans, the activity of CS-758 was at least fourfold superior to those of the other drugs tested. CS-758 also exhibited potent in vivo activity against murine systemic infections caused by C. albicans, C. neoformans, Aspergillus fumigatus, and Aspergillus flavus. The 50% effective doses against these infections were 0.41 to 5.0 mg/kg of body weight. These results suggest that CS-758 may be useful in the treatment of candidiasis, cryptococcosis, and aspergillosis.

Topics: Animals; Antifungal Agents; Aspergillus; Candida; Cryptococcus neoformans; Disease Models, Animal; Mice; Microbial Sensitivity Tests; Mycoses; Treatment Outcome; Triazoles

2002